Experimental study thalidomide for treatment of murine hepatocellular carcinoma
10.3321/j.issn:1673-4254.2005.08.002
- VernacularTitle:沙利度胺治疗肝癌的实验研究
- Author:
Yi-Ming YANG
1
;
Gang-Jun DU
;
Hai-Hong LIN
Author Information
1. First Affiliated Hospital, Henan University
- Keywords:
thalidomide;
hepatocellular carcinoma,solid/ascitic;
doxorubicin
- From:
Journal of Southern Medical University
2005;25(8):925-928
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the therapeutic effect of thalidomide(Tha) on murine hepatocellular carcinoma. Methods In murine transplanted hepatoma model, thalidomide was administered intragastrically alone (200 mg/kg daily for 10 days) or in combination with doxorubicin. The antitumor activity of Tha was observed in solid and ascitic tumor models. Results Tha induced significant growth inhibition of solid hepatoma without obvious toxicity on peripheral blood cells and lymphocyte proliferation. Although Tha alone had no effect on the survival of mice with ascitic tumor, it showed a synergistic antitumor activity in combination with doxorubicin (Dox) in both solid and ascitic tumor models. Moreover, Tha reduced Dox-induced cytopenia and immunosuppression. Histological analysis of Tha-treated tumors revealed remarkably enhanced tumor necrosis and lymphocyte infiltration on the edge of tumor tissues. Conclusion Tha has definite therapeutic effect on murine hepatoma,and the combination with Dox shows an enhanced therapeutic potential.
